Literature DB >> 24722383

Estimating the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in publicly and privately insured claims databases in the United States.

Mark Marsico1, Vinay Mehta, Benjamin Chastek, Kai-Li Liaw, Craig Derkay.   

Abstract

BACKGROUND: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a chronic disease caused by human papillomavirus types 6 and 11. It is associated with significant morbidity that places intense physical, psychological, and financial strain on patients and their families. Few studies have assessed the incidence and prevalence of JORRP in the United States.
METHODS: This retrospective, longitudinal cohort study was performed using data from a pair of large insurance claims databases in the United States. The Optum Clinformatics and Truven MarketScan Medicaid databases represent a sample of privately and publicly insured children, respectively. Cohorts of children aged 0 to 17 years were created within each database to estimate the incidence and prevalence of JORRP in 2006. Claims-based algorithms were designed to capture as many potential cases as possible. To improve the accuracy of the incidence and prevalence estimates, chart validation was performed to estimate the positive predictive value (PPV) of the claims-based algorithms.
RESULTS: The overall PPV-adjusted incidence of JORRP in 2006 was 0.51 per 100,000 in Optum and 1.03 per 100,000 in the MarketScan Medicaid population. Peak incidence was observed among 0- to 4-year-olds in both databases. The PPV-adjusted prevalence of JORRP in 2006 was 1.45 and 2.93 per 100,000 in the Optum and MarketScan Medicaid cohorts, respectively.
CONCLUSIONS: Although relatively uncommon, JORRP represents a disease with significant morbidity. The incidence and prevalence of JORRP in publicly insured children were consistently higher than those covered by private insurance plans, suggesting an increased burden of illness among those with lower socioeconomic status.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722383     DOI: 10.1097/OLQ.0000000000000115

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  13 in total

1.  Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis.

Authors:  Scott B Drutman; Filomeen Haerynck; Franklin L Zhong; David Hum; Nicholas J Hernandez; Serkan Belkaya; Franck Rapaport; Sarah Jill de Jong; David Creytens; Simon J Tavernier; Katrien Bonte; Sofie De Schepper; Jutte van der Werff Ten Bosch; Lazaro Lorenzo-Diaz; Andy Wullaert; Xavier Bossuyt; Gérard Orth; Vincent R Bonagura; Vivien Béziat; Laurent Abel; Emmanuelle Jouanguy; Bruno Reversade; Jean-Laurent Casanova
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

2.  The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.

Authors:  Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 3.  Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.

Authors:  Vivien Béziat
Journal:  Hum Genet       Date:  2020-05-20       Impact factor: 4.132

4.  High recurrence rate in patients with juvenile-onset respiratory papillomatosis and its risk factors.

Authors:  Xiaoli Qu; Yang Xiao; Lijing Ma; Zijie Niu; Jun Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-20       Impact factor: 2.503

5.  Estimated incidence of juvenile-onset recurrent respiratory papillomatosis in Korea.

Authors:  Jin-Kyoung Oh; Hwa Young Choi; Minji Han; Yuh-Seog Jung; Sang Joon Lee; Moran Ki
Journal:  Epidemiol Health       Date:  2021-03-10

Review 6.  Recurrent respiratory papillomatosis: current and future perspectives.

Authors:  Marco Carifi; Domenico Napolitano; Morando Morandi; Danilo Dall'Olio
Journal:  Ther Clin Risk Manag       Date:  2015-05-05       Impact factor: 2.423

7.  Laryngopharyngeal Reflux Is a Potential Risk Factor for Juvenile-Onset Recurrent Respiratory Papillomatosis.

Authors:  Martin Formánek; Pavel Komínek; Debora Jančatová; Lucia Staníková; Radoslava Tomanová; Jana Vaculová; Milan Urík; Ivo Šlapák; Karol Zeleník
Journal:  Biomed Res Int       Date:  2019-02-10       Impact factor: 3.411

8.  Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.

Authors:  Shelagh M Szabo; Katherine Gooch; Carol Schermer; David Walker; G Lozano-Ortega; Basia Rogula; Alison Deighton; Edward Vonesh; Noll Campbell
Journal:  BMJ Open       Date:  2019-05-05       Impact factor: 2.692

9.  Successful Treatment of Adult-Onset Recurrent Respiratory Papillomatosis with CO2 Laser and Photodynamic Therapy.

Authors:  Sheng Lu; Yang Liu; Runjie Shi; Pingyu Zhou
Journal:  Case Rep Otolaryngol       Date:  2019-10-16

10.  Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States.

Authors:  Elissa Meites; Laura Stone; Raiza Amiling; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz
Journal:  Clin Infect Dis       Date:  2021-09-07       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.